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Protease inhibitor discovery has focused almost
exclusively on compounds that bind to the active
site. Inhibitors targeting protease exosites, regions
outside of the active site that influence catalysis,
offer potential advantages of increased specificity
but are difficult to systematically discover. Here,
we describe an assay suitable for detecting exo-
site-targeting inhibitors of the metalloproteinase
anthrax lethal factor (LF) based on cleavage of a
full-length mitogen-activated protein kinase kinase
(MKK) substrate. We used this assay to screen a
small-molecule library and then subjected hits to
a secondary screen to exclude compounds that
efficiently blocked cleavage of a peptide substrate.
We identified a compound that preferentially in-
hibited cleavage of MKKs compared with peptide
substrates and could suppress LF-induced macro-
phage cytolysis. This approach should be generally
applicable to the discovery of exosite-targeting in-
hibitors of many additional proteases.
INTRODUCTION
Anthrax is caused by infection with the encapsulated spore-
forming gram-positive bacterium Bacillus anthracis (Spencer,
2003). Although the most common form of the disease is a
curable localized cutaneous infection, inhalation of anthrax
spores gives rise to a rapidly progressing, highly fatal systemic
disease. Fatality associated with inhalational anthrax has been
attributed to two plasmid-encoded secreted protein toxins,
edema toxin (EdTx) and lethal toxin (LeTx), which kill experi-
mental animals upon injection (Moayeri and Leppla, 2009).
Anthrax toxin inhibitors have been proposed as drugs that could
be used in combination with conventional antibiotics, which
alone have a poor success rate (30%) against inhalational
anthrax (Burnett et al., 2005; Holty et al., 2006).
LeTx has drawn particular attention because of its key role in
promoting anthrax virulence. LeTx consists of two proteins:
a pore-forming subunit, protective antigen (PA), which delivers
an enzymatic subunit, lethal factor (LF), into the cytosol of host
cells (Turk, 2007). LF is a zinc-dependent metalloproteinaseChemistry & Biology 19,that specifically cleaves and inactivates host mitogen-activated
kinase kinases (MKKs) at sites near their N termini. LF cleavage
disrupts interactions betweenMKKs and their MAPK substrates,
thereby terminating MAPK signaling essential for proper cell
function and survival (Duesbery et al., 1998; Vitale et al., 1998,
2000). LeTx functionally impairs cells of the immune and vascu-
lar systems, allowing spread of the disease and directly causing
pathology (Baldari et al., 2006; Moayeri and Leppla, 2009).
Many approaches taken to neutralize LeTx in vivo have
involved blocking its uptake into cells, for example by inhibiting
the LF-PA interaction or passive immunization with antibodies
to PA, and these approaches have proven effective in animal
models of toxemia and infection (Forino et al., 2005; Maynard
et al., 2002; Mourez et al., 2001; Pini et al., 2006; Rai et al.,
2006; Wild et al., 2003). However, because of prior success in
therapeutic targeting of proteases,much effort has beendirected
to the identification of LF inhibitors (Turk, 2008). Numerous
compounds that inhibit LF and block its biological activity
have been discovered through modification of known metallo-
proteinase inhibitor scaffolds, fragment-based drug discovery,
computational docking, and high-throughput screening (HTS)
using peptide substrates (Forino et al., 2005; Fridman et al.,
2005; Lee et al., 2004; Min et al., 2004; Panchal et al., 2004;
Schepetkin et al., 2006; Shoop et al., 2005; Tonello et al., 2002;
Turk et al., 2004). These approaches, although successful, are
strongly biased toward the identification of compounds target-
ing the LF active site. Such active site-directed inhibitors have
clear drawbacks, such as a tendency to cross-react with related
proteases. Such potential off target effects are particularly worri-
some in the case of anthrax, because host matrix metalloprotei-
nases can mediate defense against bacterial infections (Li et al.,
2004; Renckens et al., 2006; Wilson et al., 1999).
An alternative strategy to develop protease inhibitors is to
target exosites, generally defined as regions outside of the
active site that are important for catalysis (Bock et al., 2007;
Overall, 2002). A major function of exosites is to bind substrates
at sites separate from the cleavage site, thus promoting pro-
teolysis by increasing affinity for the substrate. Because LF
is thought to harbor an exosite required for efficient proteolysis
of MKKs (Chopra et al., 2003), we hypothesized that com-
pounds targeting this exosite would provide a means to
develop specific inhibitors of LF that could neutralize its bio-
logical activity. Previous approaches to protease exosite target-
ing have included screening phage display libraries for high-
affinity peptides, raising monoclonal antibodies against known
exosite regions, screening small-molecule libraries using model875–882, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 875
Figure 1. Identification of Compounds that
Inhibit LF Cleavage of a Full-Length MKK
Using an FP-Based Screen
(A) Assay scheme. In the absence of inhibitors,
MKK6 is cleaved, releasing a small fluorescent
fragment having decreased FP. In the presence of
an inhibitor, higher quantities of full-length MKK6
provide an increased FP signal.
(B) Scheme for purification and N-terminal TGase-
mediated labeling of MKK6.
(C) SDS-PAGE analysis of LF-cleaved N-terminally
labeled MKK6. Fluorescein fluorescence (top
panel) and total protein (bottom panel) is shown
for 2 mM labeled MKK6 treated with the indicated
concentrations of LF for 30 min at RT.
(D) Z0 values for each plate from the primary screen
of 2835 molecules.
(E) Hit identification. Thirteen compounds showed
greater than 30% inhibition relative to control
reactions run in the absence of added compound.
See also Figure S1.
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discovery of exosite-blocking compounds (Bjo¨rklund et al.,
2004; Dennis et al., 2000; Hardy et al., 2004; Lauer-Fields
et al., 2009; Mikkelsen et al., 2008; Silha´r et al., 2010). Here we
describe HTS to identify LF inhibitors using a full length MKK,
rather than a short peptide, as a substrate. In addition to classic
active site-binding compounds, such a screen is capable of
identifying molecules that target the exosite. By this approach,
we have identified a small molecule that preferentially inhibits
cleavage MKK protein substrates over short peptide substrates
and blocks LF cytotoxicity. These results validate our approach
to the discovery of exosite-targeting protease inhibitors.
RESULTS
A Screen for Small Molecules that Inhibit LF Cleavage of
a Full-Length Protein Substrate
We developed an LF protease assay suitable for HTS that takes
advantage of the N-terminal location of its cleavage sites within
MKKs. Proteolysis of anMKK conjugated to a fluorophore at its N
terminus liberates a low-molecular-weight fluorescent peptide
(Figure 1). The labeled fragment can be distinguished from full-
length MKK by a change in fluorescence polarization (FP). In876 Chemistry & Biology 19, 875–882, July 27, 2012 ª2012 Elsevier Ltd All rights reservedthe absence of an inhibitor, LF cleavage
produces a low FP signal, whereas a hit
compound would prevent cleavage and
thus provide a high FP signal.
We used MKK6 as a substrate,
because we could produce large quanti-
ties of the full-length protein, suffi-
cient for HTS, in bacteria. As previously
demonstrated for MKK1 (Chopra et al.,
2003), we found that efficient proteoly-
sis of MKK6 by LF required its intact
kinase domain, indicating that cleavage
is exosite dependent (see Figure S1 avail-
able online). We engineered an efficientacceptor site for the enzyme transglutaminase (TGase) that
had previously been identified by phage display (Sugimura
et al., 2006) into the N terminus of MKK6 (Figure 1B). This
enabled TGase-catalyzed conjugation of fluorescein cadaverine
close to the protein N terminus. Labeling occurred to high stoi-
chiometry (78% ± 8% among four separate labeling reactions)
and was specific to the intended site, as LF cleavage decreases
the abundance of fluorescent MKK6 and produces a nonfluores-
cent cleavage product (Figure 1C).
Optimization of LF (20 nM) andMKK6 (125 nM) concentrations
in a 384-well plate assay format provided a Z0 value of 0.61 suit-
able for HTS (Zhang et al., 1999). We confirmed that the known
peptide hydroxamate inhibitor GM6001 (Turk et al., 2004) scored
as a hit in this assay. We then used the assay to screen a collec-
tion of 2,835 small molecules and natural product extracts.
Among LF inhibitors identified from this screen was epiafzele-
chin, a compound structurally similar to green tea flavonoids
previously described as LF inhibitors (Dell’Aica et al., 2004).
We identified 13 primary hits overall at a threshold of 30% inhibi-
tion (Figure 3B). Hit compounds were subjected to a secondary
screen using a short fluorogenic peptide substrate to exclude
active site-targeting inhibitors. Finally, hits that showed dose-
dependent inhibition in the primary assay were confirmed using
Table 1. Lichen Compounds and Their Potency for LF Inhibition
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out compound interference. By these criteria, stictic acid
(StA, compound 1 in Table 1), a depsidone natural product
from lichens (Lawrey, 1986), was the only hit found to specifically
inhibit MKK6 cleavage.
Characterization of Depsidone Inhibitors of LF
The StA structure comprises substituted benzaldehyde and
benzofuranone groups flanking a central seven-membered
lactone ether ring. To identify specific features required for
LF inhibition, an initial series of six commercially available StA
analogs (Table 1) were obtained and evaluated for their ability
to block MKK6 cleavage in the SDS-PAGE mobility shift assay
(Figure 2A). Although two of the compounds, salazinic acid (2)
and parellic acid (3), were active as inhibitors, the remaining
analogs had no observable activity. Inhibition by 3 indicates
that the furanone ring is dispensable for inhibition. However,Chemistry & Biology 19,lack of inhibition by 6 and 7 suggests that the central seven-
membered lactone ring is essential. We also noted that
compounds 4 and 5, which lack the free aldehyde group, failed
to inhibit LF. To formally evaluate the importance of the alde-
hyde, we synthesized and tested reduced forms of 1 and 3
(compounds 8 and 9, respectively). For both compounds, reduc-
tion of the aldehyde to an alcohol diminished but did not
completely eliminate LF inhibition, suggesting that the alde-
hyde is important but not absolutely essential for activity. We
observed no detectable inhibition of MKK6 cleavage by o-anisal-
dehyde, a simple benzaldehyde, at concentrations up to 2 mM
(not shown), indicating that LF inhibition by depsidones is not
due to nonspecific reactivity of the aldehyde group.
Of all compounds tested, StA was the most potent, inhibiting
cleavage of MKK6 with an IC50 of 24 ± 3 mM, whereas 2 and 3
had decreased potency (Figure 2 and Table 1). Although
compound interference prevented us from performing a full
dose response, each compound only weakly inhibited cleavage
of a peptide substrate at the highest concentration tested
(100 mM, Figure 2D). For comparison we used both the protein
and peptide cleavage assays to evaluate the active site inhibitor
GM6001. GM6001 inhibited LF cleavage of MKK6 with an IC50
value of 45 mM, similar potency to StA (Table 1 and Figure S2).
However, unlike StA, GM6001 more potently inhibited peptide
cleavage (IC50 = 9 mM). The weaker potency of the standard
active site-binding inhibitor observed with the MKK substrate
compared with the peptide substrate may be because accurate
quantification in the SDS-PAGE assay required overdigestion
of the substrate (noninitial velocity conditions). Nonetheless,
the observation that depsidones blocked cleavage of an MKK
substrate more potently than they do a peptide substrate under-
scores that they work by mechanism distinct from that of
a conventional inhibitor. Although accurate kinetic analysis of
the mode of inhibition was hampered by the gel-based cleavage
assay, we found that compound 2 reproducibly increased KM
with no effect on Vmax (Figure 2E). These data suggest that dep-
sidones act as competitive inhibitors of LF, consistent with
disruption of the LF-MKK6 interaction through exosite binding.
Because we had found depsidones to be substrate-specific
inhibitors of LF, we further assessed the ability of these
compounds to block cleavage of MKKs other than MKK6.
Compounds 1, 2, and 3 each inhibited cleavage of both MKK3
and MKK4 in lysates from RAW264.7 cells, used as a source of
endogenous MKKs (Figure 2F). These experiments indicate
that depsidones are general inhibitors of MKK protein cleavage
by LF.
Depsidone Inhibitors Neutralize LeTx Activity in
Cultured Cells
To assess the capacity of the new class of LF inhibitors to
neutralize the biological activity of LeTx, we examined the effect
of depsidones on MKK cleavage and cell viability in LeTx-
treated macrophage cells. RAW264.7 cells were pretreated
with compounds 1, 2, or 3 prior to adding LeTx. Cells were
harvested 1 hr after treatment, a time subsequent to LF uptake
but prior to cell death. Immunoblot analysis (Figure 3A) showed
that all three depsidones decreased MKK3 cleavage in intact
cells. In separate experiments, we preincubated cells with com-
pounds before adding varying amounts of LF in the presence of875–882, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 877
Figure 2. LF Inhibition by Lichen
Compounds
(A) Structure-activity profile of StA analogs.
Compounds (250 mM) were mixed with LF (25 nM)
and MKK6 (1 mM) for 30 min at room temperature
prior to electrophoresis.
(B) Inhibitor titration for the three active
compounds, performed as in (A) with the indicated
concentrations of compound.
(C) Quantified inhibition curves. The average ±
standard deviation is shown for three separate
experiments performed as shown in (B).
(D) Depsidones are weak inhibitors of LF cleavage
of a peptide substrate. Initial rates of peptide
cleavage were measured by continuous fluoro-
metric assay in the presence of compounds 1, 2,
and 3 (at 100 mM) or GM6001 (GM, 50 mM). The
percentage activity relative to the vehicle control ±
standard deviation is shown for data collected in
triplicate.
(E) Depsidones inhibit LF cleavage of MKK6
competitively. LF was incubated with varying
concentrations of MKK6 in the presence of the
indicated concentrations of compound 2. The
double reciprocal plot displaying the data has
lines intersecting at the y-axis, consistent with
competitive inhibition.
(F) Inhibition of MKK3 and MKK4 cleavage by
depsidones. RAW264.7 cell lysate was incubated
with compounds 1–3 (250 mM) followed by LF
(0.03 mg/ml) for 30 min at RT. MKK3 and MKK4
cleavage was analyzed by immunoblotting.
See also Figure S2.
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viability by MTT assay. In the absence of compounds, LF
causes dose-dependent killing of these cells (Figure 3B). Each
of the depsidones capable of inhibiting LF (1, 2, and 3) provided
partial protection against LeTx-induced cell death, even at
LF concentrations causing complete killing. By contrast, the
inactive ring-opened analogs 6 and 7 failed to inhibit cell
death. These experiments indicate that depsidone LF in-
hibitors display target-specific biological activity and may
therefore be candidates for further development into anthrax
therapeutics.
DISCUSSION
Exosites were first identified in proteases in the coagulation
cascade as binding sites for substrates and allosteric modula-
tors (Bock et al., 2007). To date, derivatives of the leech antico-
agulant protein hirudin, which binds both the exosite and the
active site in a bivalent manner, remain the only clinically
approved exosite-targeting protease inhibitors (Di Nisio et al.,
2005). Interest in targeting exosites for other proteases has
arisen from the failure to develop highly selective inhibitors for
important therapeutic targets (Drag and Salvesen, 2010; Kor-
nacker et al., 2005; Matheson and Goa, 2000). Although the
identification of conventional active site inhibitors can rely on
derivatization of scaffolds that target a given class of proteases
(i.e., peptide hydroxamates for metalloproteinases), the dis-
covery of exosite-targeting inhibitors has not been straightfor-
ward. Standard HTS using peptide substrates can identify878 Chemistry & Biology 19, 875–882, July 27, 2012 ª2012 Elsevier Lallosteric inhibitors that bind to exosites, and several classes of
polyphenolic compounds have been identified as noncompeti-
tive LF inhibitors (Min et al., 2004; Numa et al., 2005). However,
allosteric inhibitors discovered in this manner must by definition
influence the enzyme active site. By contrast, identification of
inhibitors that bind substrate-recruiting exosites cannot be
identified using short peptide substrates. Such inhibitors work
by blocking a protein-protein interaction and may be regarded
as difficult to discover by HTS, even with the appropriate
assay. However, substrate recruitment sites in protein modifying
enzymes tend to be grooves or pockets that bind to short
peptide structures, interactions more amenable to disruption
with small molecules than those involving large interaction
surfaces (Arkin and Whitty, 2009). Indeed, the recent seren-
dipitous discovery of small molecules that disrupt exosite
interactions with the botulinum neurotoxin metalloproteinase
supports the feasibility of therapeutic exosite targeting (Silha´r
et al., 2010).
The identification of such exosite-targeting protease inhibi-
tors, however, requires novel approaches distinct from conven-
tional HTS. Exosite-binding peptides for proteases have been
selected from phage display libraries (Dennis et al., 2000,
2001; Kornacker et al., 2005) and from known exosite-binding
regions of substrates (Lauer-Fields et al., 2008). In addition, exo-
site-blocking monoclonal antibodies have been produced for
several proteases (Atwal et al., 2011; Mikkelsen et al., 2008).
However, peptide- and antibody-based therapeutics have unde-
sirable pharmacology, and particularly for an intracellular target,
small-molecule inhibitors are advantageous. A fragment-basedtd All rights reserved
Figure 3. Depsidones Neutralize LeTx Activity on Cultured Cells
(A) RAW264.7 cells were pretreated with either DMSO carrier or 400 mM of
the indicated compound and then were incubated with 0.03 mg/ml LF and
0.5 mg/ml PA. After 1 hr, cell lysates were extracted and analyzed by immu-
noblotting to detect MKK3 cleavage. Vinculin levels were detected by immu-
noblotting the same samples as a loading control.
(B) RAW264.7 cells were pretreated with either DMSO carrier or 400 mM of the
indicated compound followed by various concentrations of LF in the presence
of 0.5 mg/ml PA. After 4 hr, cell viability was determined by MTT assay. Data
points show the average of three determinations, and error bars show the
standard deviation.
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has been used to identify allosteric small-molecule inhibitors of
caspases that bind through novel sites, though the approach
requires the presence of reactive amino acids at the exosite
(Hardy et al., 2004). We have taken an alternative approach
using HTS with an exosite-dependent substrate. Fields and
coworkers identified a substrate-selective matrix metalloprotei-
nase-13 inhibitor by HTS using model triple helical peptide
substrates whose cleavage is exosite-dependent (Lauer-Fields
et al., 2009). However, to our knowledge, our study is the first
report of HTS using a full-length protease substrate. Although
the FP assay used requires that cleavage occur close to one
terminus of the substrate, FRET or LRET-based assays without
such restrictions could also be generated by dual labeling of
the substrate (Yang and Yang, 2009).
The sole MKK-specific LF inhibitor identified in our primary
screen was the depsidone StA. Depsidones and related
compounds are lichen secondary metabolites that are thought
to provide protection against UV light, pollutants, oxidative
stress, and harmful microbes (Molna´r and Farkas, 2010). Lichen
metabolites have attracted some attention as potential thera-
peutics. For example, depsidones were discovered through
HTS as moderate HIV integrase inhibitors and have also been
found to induce apoptosis of a prostate cancer cell line (Neamati
et al., 1997; Russo et al., 2006). Lichen compound activity
in these assays follows a distinct structure-activity relationshipChemistry & Biology 19,in comparison to LF inhibition, suggesting that it should be
possible to identify depsidone analogs with specificity for LF.
In addition to offering a novel scaffold for LF inhibition,
depsidones may also find use as structural probes to charac-
terize the LF exosite. Despite its importance for MKK cleavage,
specific residues comprising the LF exosite remain to be
discovered. The depsidone binding site may overlap with the
LF exosite, or alternatively may allosterically influence exosite
interactions. Crystallography of LF in complex with active site
inhibitors uncovered critical details of cleavage site recognition
(Turk et al., 2004). Similarly, we expect that structural character-
ization of an LF-depsidone complex will provide insight into
the LF exosite. The importance of the aldehyde group for dep-
sidone activity suggests that it may form a covalent complex
with LF. Identification of the residue modified by the com-
pounds could thereby provide a means to map the depsidone
binding site.
SIGNIFICANCE
Proteolytic enzymes have emerged as important drug
targets. Although conserved features within protease active
sites have been exploited in the development ofmechanism-
based inhibitors for all protease classes, specific targeting
of individual proteases remains a formidable challenge.
Here we have described a systematic approach to target
exosites, which are generally unique to individual pro-
teases, as a means to identify specific inhibitors. Using
this approach, we have identified substrate-specific inhibi-
tors of anthrax lethal factor, a known virulence factor and
potential target for anthrax therapeutics. These molecules
provide an important research tool, both in the manipulation
of LF activity in experimental systems and as structural
probes for better understanding exosite interactions. Our
approach should be generally useful for discovering exosite
probes for other proteases as well.
EXPERIMENTAL PROCEDURES
Materials
Recombinant LF and PA were from List Biological Laboratories. StA was
obtained from Sigma-Aldrich. Compounds 4, 6, and 7 were obtained from
Chromadex. Compounds 2 (NSC 87509), 3 (NSC 92186), and 5 (NSC 5916)
were obtained from the NCI/DTP Open Chemical Repository (http://dtp.
cancer.gov). Compound 3 for chemical modification was obtained from MP
Biomedical.
FP Assay and Inhibitor Screening
Production of N-terminally labeled MKK6 for HTS is described in Supple-
mental Experimental Procedures. Screens were conducted at the Yale
Small Molecule Discovery Center using a Tecan Aquarius robot in combina-
tion with a Freedom EVO Workstation. A V&P Scientific 384-pin tool trans-
ferred small molecules (10 mM stock) from library plates into black
384-well assay plates containing assay buffer (20 mM HEPES [pH 7.4],
0.1 mg/ml BSA, 10 mM CaCl2, and 0.01% Brij35). Assays were performed
in a total volume of 20 ml with final concentrations of 10 mM compound,
125 nM MKK6, and 20 nM LF. FP was read after 60 min incubation at RT
on a Wallac Envision plate reader equipped with fluorescein filters. Each
assay plate included reactions without added compounds and reactions
without lethal factor to set high and low boundaries for FP signals, respec-
tively. Z0 analysis (Zhang et al., 1999) was done from 32 maximum control
values (c+) and 32 minimum controls (c) on each plate. Assays were875–882, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 879
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ered robust. Screening was performed against five libraries: NIH Clinical
Collection 1 (450 compounds), the Yale Compound Repository (a collection
of 250 compounds synthesized by Yale chemists), the Gen-Plus (960
compounds) and Pure Natural Products (800 compounds) collections from
MicroSource Discovery Systems, and the Yale Rainforest Collection (393
bacterial or fungal extracts).
SDS-PAGE-Based Cleavage Assay
LF (25 nM in assay buffer) was mixed with compound at the indicated
concentration, and the reaction was initiated by adding unlabeled MKK6 to
1 mM and stopped after 30 min at RT by adding 43 SDS-PAGE loading
buffer. For determination of IC50 values, reaction was performed with
compound concentrations ranging from to 7.8 to 250 mM in 2-fold incre-
ments. Samples were subjected to SDS-PAGE (10% acrylamide), stained
with Coomassie, scanned with a flatbed scanner, and analyzed using
Quantity One (BioRad) or ImageJ (National Institutes of Health) software to
quantify band intensities. The extent of inhibition was determined by
measuring the intensity of the band corresponding to the cleavage product
in the absence or presence of compound. IC50 values were determined
by fitting to the following equation: percentage inhibition = 100 3 [I] /
(IC50 + [I]). Reported values are the average ± standard deviation of three
separate measurements. To determine the mode of inhibition, LF (10 nM)
was incubated with a range of MKK6 concentrations flanking the KM value
(2-fold increments from 0.5 to 16 mM) in the presence at varying inhibitor
concentration. Samples were diluted so that an equal amount of MKK6
was run in each lane of an SDS-polyacrylamide gel, and the extent of
cleavage was quantified as described above.
Peptide Cleavage Assay
Cleavage was assayed using the LF optimized fluorescent substrate
Mca-AKVYPYPME-Dnp (Turk et al., 2004), where Mca is the fluorophore
7-methoxycoumarin-4-acetic acid and Dnp is the quencher 2,4-dinitro-
phenyldiaminopropionic acid. LF (100 nM) in 20 mM HEPES (pH 7.4),
0.1 mg/ml BSA, and 0.1% Brij35 was incubated with 10 mM peptide in
the presence of compound or vehicle (1% DMSO), and fluorescence was
monitored at excitation and emission wavelengths of 325 nm and 393 nm,
respectively. Cleavage rates were calculated from kinetic measurements
taken once per minute during the initial rate period. Assays were performed
in triplicate.
Assay of MKK Cleavage in Cell Lysates
RAW264.7 cells were cultured in DMEM containing 10% fetal bovine
serum. Cells were grown to confluence in 10 cm plates, washed twice with
ice-cold phosphate-buffered saline, and extracted into RAW cell lysis
buffer (20 mM HEPES [pH 7.4], 100 mM NaCl, 0.5% NP40, 10 mg/ml
leupeptin, 2 mg/ml pepstatin A, 10 mg/ml aprotinin, 1 mM DTT, and 1 mM
PMSF) and cleared by centrifugation (10 min at 16,000 3 g). Clarified
lysates were mixed with DMSO or compound to 250 mM, and LF was
immediately added to 50 nM prior to incubation for 30 min at RT.
Reactions were subjected to SDS-PAGE followed by immunoblotting with
anti-MKK3 and anti-MKK4 antibodies (Cell Signaling Technology, dilution
1:2000).
Inhibition of MKK Cleavage in Intact Cells
RAW264.7 cells were plated in 6-well dishes at 1.2 3 107 cells per well and
were allowed to recover overnight. After exchanging to fresh media, cells
were preincubated for 30 min with 400 mM compound or 4% DMSO control.
PA (0.5 mg/ml) and LF (0.01 mg/ml) were then added, and plates were
incubated at 37C for 1 hr. Cells were then washed once with ice-cold
phosphate-buffered saline and then extracted into RAW cell lysis buffer.
Lysates were cleared by centrifugation and subjected to SDS-PAGE fol-
lowed by immunoblotting with anti-MKK3 or antivinculin antibody as a loading
control.
Cytotoxicity Assay
RAW264.7 cells were plated in 96-well dishes at 4 3 105 cells per well and
were allowed to recover for 16 hr, after which the medium was removed880 Chemistry & Biology 19, 875–882, July 27, 2012 ª2012 Elsevier Land replaced with fresh complete medium (100 ml per well) containing
400 mM compound or 4% DMSO vehicle control. After 30 min, PA
(0.5 mg/ml) and/or LF (0.001–0.3 mg/ml) were added and incubation
continued for an additional 4 hr. To assay viability, 10 ml of 5 mg/ml
MTT in PBS was added to each well, and incubation was continued for
2 hr before aspirating the supernatant and extracting with 0.1 M HCl in
isopropanol. Absorbance at 570 nm with a background correction at
690 nm was determined in an absorbance plate reader. Experiments were
done in triplicate and repeated three independent times for each of the
inhibitors tested. The results are presented as the average ± standard
deviation.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.chembiol.2012.05.013.
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